Agios Pharmaceuticals to Present New Data on PK Activators Mitapivat and Tebapivat at EHA 2025 Congress

Agios Pharmaceuticals will present new data on PK activators at the EHA Congress, focusing on rare blood disorders.

Quiver AI Summary

Agios Pharmaceuticals announced that it will present new data on its pyruvate kinase activators, mitapivat and tebapivat, during the 30th European Hematology Association (EHA) Congress in Milan from June 12-15, 2025. The presentations will showcase clinical and preclinical findings related to rare blood disorders, including sickle cell disease, thalassemia, and myelodysplastic syndromes. Highlights include results from the ACTIVATE-KidsT study, which demonstrated mitapivat's efficacy in reducing transfusion needs in pediatric PK deficiency patients, and long-term data from the ESTIMATE Phase 2 trial showing mitapivat's sustained efficacy in sickle cell patients. Additionally, preclinical data will be presented on tebapivat's potential in reducing red blood cell sickling. Agios aims to strengthen its collaboration with the global hematology community through these presentations.

Potential Positives

• Agios Pharmaceuticals will present significant new data on its PK activators, mitapivat and tebapivat, at the prestigious 30th EHA Congress, enhancing visibility within the global hematology community.
• The ACTIVATE-KidsT Phase 3 study presents promising results, highlighting a meaningful reduction in transfusion burden for children with PK deficiency, demonstrating the potential effectiveness of mitapivat.
• Long-term data from the ESTIMATE Phase 2 trial shows sustained efficacy and tolerability of mitapivat in sickle cell disease patients, indicating a strong potential for long-term treatment benefits.
• Agios' focus on serious conditions with limited treatment options underscores its commitment to addressing unmet medical needs in rare blood disorders, positioning the company as a leader in this niche therapeutic area.

Potential Negatives

• The prespecified statistical criterion for the ACTIVATE-KidsT study of mitapivat was not met, which may raise concerns about the robustness of the results.
• The press release includes significant caution regarding potential adverse reactions to PYRUKYND, such as acute hemolysis and hepatocellular injury, which could impact patient safety perceptions and market confidence.
• Forward-looking statements indicate uncertainty regarding the ability to progress product candidates through clinical development phases, which could affect future business prospects and investor sentiment.

FAQ

What new data will Agios present at EHA 2025?

Agios will present data on mitapivat and tebapivat therapies for rare blood disorders, including sickle cell disease and thalassemia.

When is the EHA 2025 Congress?

The 30th European Hematology Association Congress will take place from June 12-15, 2025, in Milan, Italy.

What diseases are targeted by Agios' PK activators?

Agios' PK activators target rare blood disorders like sickle cell disease, thalassemia, PK deficiency, and myelodysplastic syndromes.

What are the results of the ACTIVATE-KidsT study?

The ACTIVATE-KidsT study showed a reduction in transfusion burden in children with PK deficiency treated with mitapivat.

What is the significance of Agios' research at EHA 2025?

The research emphasizes the potential of PK activation therapies to provide meaningful treatment options for patients with rare blood disorders.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$AGIO Congressional Stock Trading

Members of Congress have traded $AGIO stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $AGIO stock by members of Congress over the last 6 months:

• REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 04/17, 01/29 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$AGIO Insider Trading Activity

$AGIO insiders have traded $AGIO stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.

Here’s a breakdown of recent trading of $AGIO stock by insiders over the last 6 months:

• BRIAN GOFF (Chief Executive Officer) has made 0 purchases and 2 sales selling 12,947 shares for an estimated $460,136.
• JACQUALYN A FOUSE sold 7,497 shares for an estimated $194,172
• TSVETA MILANOVA (Chief Commercial Officer) has made 0 purchases and 2 sales selling 4,485 shares for an estimated $149,975.
• SARAH GHEUENS (Chief Medical Officer) has made 0 purchases and 3 sales selling 4,005 shares for an estimated $142,337.
• THEODORE JAMES JR. WASHBURN (Principal Accounting Officer) sold 2,272 shares for an estimated $78,134
• DAVID SCADDEN sold 200 shares for an estimated $9,256

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$AGIO Hedge Fund Activity

We have seen 110 institutional investors add shares of $AGIO stock to their portfolio, and 120 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• JEFFERIES FINANCIAL GROUP INC. removed 1,500,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $43,950,000
• CITADEL ADVISORS LLC added 1,421,940 shares (+12116.1%) to their portfolio in Q4 2024, for an estimated $46,724,948
• VESTAL POINT CAPITAL, LP removed 760,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $24,973,600
• MARSHALL WACE, LLP removed 631,657 shares (-50.0%) from their portfolio in Q4 2024, for an estimated $20,756,249
• PRICE T ROWE ASSOCIATES INC /MD/ removed 408,975 shares (-14.4%) from their portfolio in Q4 2024, for an estimated $13,438,918
• POLAR CAPITAL HOLDINGS PLC removed 375,000 shares (-37.4%) from their portfolio in Q4 2024, for an estimated $12,322,500
• ADAGE CAPITAL PARTNERS GP, L.L.C. added 303,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $9,956,580

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company’s PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30

^th

European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025.

“The clinical results and scientific insights being presented at EHA add to the robust body of efficacy and safety data demonstrating the promise of PK activation in treating both adults and children with rare blood disorders,” said Sarah Gheuens, M.D., Ph.D., Chief Medical Officer and Head of R&D, Agios. “The presentations span serious conditions with limited or no treatment options, including sickle cell disease, thalassemia, PK deficiency, and myelodysplastic syndromes, offering meaningful results that highlight the therapeutic potential of mitapivat and tebapivat. We look forward to this important opportunity to share these new data and strengthen our collaboration with the global hematology community at EHA.”

Select presentations and publications at EHA 2025 will include:

• 
  An oral presentation of results from the ACTIVATE-KidsT Phase 3 study of mitapivat in children aged 1 to <18 years with PK deficiency who are regularly transfused. The study showed a clinically meaningful reduction in transfusion burden with mitapivat, with a higher proportion of patients achieving the primary endpoint of transfusion reduction response compared to placebo, though the prespecified statistical criterion was not met. Safety results were consistent with the safety profile for mitapivat previously observed in adults with PK deficiency who are regularly transfused. The ACTIVATE-KidsT study, along with the positive ACTIVATE-Kids Phase 3 trial, represents the successful execution of Agios’ first pediatric clinical program.
  


• 
  An oral presentation of long-term data from the investigator-led ESTIMATE Phase 2 trial, an open-label study investigating mitapivat in patients with sickle cell disease. In the study, mitapivat showed sustained efficacy and tolerability over three years, including improvements in anemia, hemolysis, painful vaso-occlusive crises, and markers of kidney damage.
  


• 
  A poster presentation with preclinical data demonstrating that tebapivat reduced red blood cell sickling and adhesion in blood samples from sickle cell disease patients, highlighting its therapeutic potential in this patient population.
  


• 
  A preclinical publication examining expression patterns of PKM2, an isoform (or variant) of the PK enzyme. The study found that, compared with healthy controls, patients with myelodysplastic syndromes (MDS) have significantly reduced PKM2 expression in CD34+ hematopoietic stem cells, which may be implicated in the development of MDS. These findings further support the ongoing investigation of tebapivat in lower-risk MDS, as it activates PKM2 in addition to PKR (the PK isoform found in red blood cells).
  

In total, 14 presentations and publications led by Agios and external collaborators will be shared at EHA 2025.

EHA 2025 Accepted Abstracts

*This investigator-sponsored trial is part of a larger project funded by Agios

Please refer to the

EHA 2025 online program

for full session details and data presentation listings, and visit the Agios booth (#C04) onsite.

About PYRUKYND



^®



(mitapivat)




U.S.


INDICATION



PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

U.S. IMPORTANT SAFETY INFORMATION




Acute Hemolysis:

Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Hepatocellular Injury in Another Condition:

In patients with another condition treated with PYRUKYND at a higher dose than that recommended for patients with PK deficiency, liver injury has been observed. These events were characterized by a time to onset within the first 6 months of treatment with peak elevations of alanine aminotransferase of >5× upper limit of normal (ULN) with or without jaundice. All patients discontinued treatment with PYRUKYND, and these events improved upon treatment discontinuation.

Obtain liver tests prior to the initiation of PYRUKYND and monthly thereafter for the first 6 months and as clinically indicated. Interrupt PYRUKYND if clinically significant increases in liver tests are observed or alanine aminotransferase is >5x ULN. Discontinue PYRUKYND if hepatic injury due to PYRUKYND is suspected.

Adverse Reactions:

The most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

Drug Interactions:

• 
  Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
  


• 
  Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
  


• 
  Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
  


• 
  Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
  


• 
  UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
  


• 
  P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
  

Hepatic Impairment:

Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

Please see



full Prescribing Information



for PYRUKYND.

About Agios



Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at

www.agios.com

.

Cautionary Note Regarding Forward-Looking Statements



This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of PYRUKYND

^®

(mitapivat) and tebapivat; Agios’ plans regarding future data presentations; and the potential benefits of Agios’ strategic plans and focus. The words “anticipate,” “expect,” “goal,” “hope,” “milestone,” “plan,” “potential,” “possible,” “strategy,” “will,” “vision,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios’ ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of TMPRSS6 siRNA, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios’ cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

Investor Contact



Morgan Sanford, Vice President, Investor Relations


Agios Pharmaceuticals



IR@agios.com

Media Contact



Eamonn Nolan, Senior Director, Corporate Communications


Agios Pharmaceuticals



Media@agios.com